EBIT +5% vs. ABGSCe, 21% org. growth, 39% margins (ABGSCe 36%) Slightly slower ramp-up vs.
Board recommends shareholders to REJECT Kingspan bid Increases the chance of a raised bid, in our vi...
Redeye comments on GiG ahead of its Q4-results (due 14 February) where we expect the company to deli...
Redeye comments on Scandion Oncology presenting more details on CORIST part 3 results at its recent ...
Q4: Clean EBIT of SEK -100m Pulp prices up and demand better Fair value range: SEK 9-16/sh Q4: Figu...
Q4e revenue ~NOK 306m Sainsbury's contract a positive development, but more orders needed Estimates ...
Analyst Group has entered into an agreement with Pharma Equity Group on commissioned research, inclu...
Redeye shares its preview of BONESUPPORT’s Q4 2023e results, due February 15.
Equity analyst interviews Elanders' CEO Magnus Nilsson and CFO Andreas Wikner after their Q4.
Inför rapporten för det fjärde kvartalet förväntar sig Analysguiden tillväxt inom samtliga marknader...
A SEK 20m to SEK 35m financing based with the financial partner Formue Nord Fokus A/S eases the fina...
Carasent has entered into an agreement to sell the Confrere brand and customer contracts to Compodiu...
Having already achieved proof-of-performance for its proprietary digital technique for detection of ...
Vitrolife’s Q4 delivers a high 56.9% gross margins despite a quarter with an unfavorable Technology ...
Redeye updates its estimates and valuation following Lifco’s Q4 2023 report.
Redeye returns with an update following Hoylu’s Q4 2023 report that missed our expectations across t...
Ferronordic will report its Q4 2023 results on 22 February.
Redeye has updated its estimates and valuation following Kontigo Care’s Q4’23 report.
5.2% organic sales growth, improving margins EBITDA up 1.
Redeye highlights two positive developments for Acarix: a SEK33.
